Comparison / Study ID (number of participants) | Outcome | RR |
95% CI lower limit |
95% CI upper limit |
rATG: single 6 mg/kg versus 4 x 1.5 mg/kg doses (same total dose) | ||||
Stevens 2008 (142) | Death at 6 months | 0.34 | 0.01 | 8.27 |
Graft loss (all cause) at 6 months | 0.21 | 0.01 | 4.21 | |
Acute rejection | 0.69 | 0.26 | 1.83 | |
Delayed graft function | 2.40 | 0.65 | 8.91 | |
Malignancy/PTLD | 0.21 | 0.01 | 4.21 | |
BKV | 0.15 | 0.01 | 2.79 | |
Severe febrile reaction (anaphylaxis requiring ICU) | 1.03 | 0.15 | 7.10 | |
Serum sickness | 0.21 | 0.01 | 4.21 | |
NODAT | 0.82 | 0.47 | 1.42 | |
ATG: 2 x3 mg/kg versus 4 x 1.5 mg/kg doses (same total) | ||||
Buchler 2013 (17) | ** | ‐ | ‐ | ‐ |
ATG: adjusted for CD3 count versus fixed dose of 15 mg/kg/d | ||||
Abouna 1995 (45) | Death at 2 years | 0.96 | 0.06 | 14.37 |
Graft loss (all cause) 2 years | 0.72 | 0.18 | 2.85 | |
Acute rejection | 0.96 | 0.5 | 1.84 | |
Leucopenia | 0.36 | 0.11 | 1.18 | |
Thrombocytopenia | 0.14 | 0.01 | 2.51 | |
Viral infection (all cause) | 0.96 | 0.15 | 6.21 | |
Bacterial infection (all cause) | 0.64 | 0.21 | 1.96 | |
ATG: adjusted by CD3 count versus adjusted by total lymphocytes | ||||
Ata 2013 (21) | ** | ‐ | ‐ | ‐ |
ATG: standard (3.75 mg/kg total) versus low dose (2.25 mg/kg total) | ||||
Grafals 2014 (43) | Acute rejection at 1 year | 0.57 | 0.12 | 2.81 |
Leucopenia | 0.69 | 0.31 | 1.56 | |
Severe infection | 0.77 | 0.14 | 4.14 | |
CMV infection | 0.23 | 0.01 | 4.50 | |
BKV infection | 0.38 | 0.02 | 8.86 | |
Death at 1 year | 8.00 | 0.44 | 146.08 | |
Delayed graft function | 3.07 | 0.94 | 10.02 | |
Malignancy at 1 year | 2.30 | 0.23 | 23.51 | |
PTLD at 1 year | 0 events | not estimable | ||
Graft function at 1 year (SCr, µmol/L) | 6.00* | 1.07 | 10.93 | |
OKT3: standard dose (5 mg) versus low dose (2 mg) | ||||
Norman 1993a (26) | Death at 1 year | 0 events | not estimable | |
Graft loss at 1 year | 3 | 0.13 | 67.51 | |
Acute rejection | 0.2 | 0.01 | 3.8 | |
Delayed graft function | 1.25 | 0.43 | 3.63 | |
CMV | 4 | 0.51 | 31.13 | |
Herpes Simplex virus | 0.5 | 0.05 | 4.86 | |
Bacterial | 0.86 | 0.4 | 1.86 | |
Fungal | 1 | 0.16 | 6.07 | |
Malignancy | 4.72 | 0.23 | 96.59 | |
OKT3: standard dose (5 mg) versus high dose (10 mg) | ||||
Abramowicz 1994 (29) | Death at 3 months | 0 events | not estimable | |
Graft loss at 3 months | 4.69 | 0.24 | 89.88 | |
Acute rejection to 3 months | 0.47 | 0.1 | 2.16 | |
Delayed graft function | 0.93 | 0.34 | 2.54 | |
ALG: low versus high dose | ||||
Sakhrani 1992 (83) | Death at 1 year | 0.89 | 0.41 | 1.97 |
Acute rejection | 0.86 | 0.48 | 1.55 | |
Leucopenia | 0.5 | 0.18 | 1.41 | |
Severe infection | 1.05 | 0.52 | 2.11 | |
ALG: 14 days versus 7 days | ||||
Grundmann 1987 (100) | Death 1 year | 0 events | not estimable | |
Graft loss (all cause) 1 year | 0.29 | 0.06 | 1.31 | |
Acute rejection | 0.5 | 0.05 | 5.34 | |
Delayed graft function | 0.62 | 0.28 | 1.35 | |
Pneumonia | 3 | 0.13 | 71.92 | |
Wound infection | 0 events | not estimable | ||
Treatment stopped due to side effects | 63 | 3.96 | 1002.01 | |
Graft function at 1 year (SCr, µmol/L) | ‐35.4* | ‐78.72 | 7.92 | |
ALG: high versus low potency | ||||
Thomas 1977 (71) | Acute rejection at 3 months | 4.14 | 1.55 | 11.00 |
Graft loss at 1 year | 2.53 | 1.30 | 4.90 |